Onyx Biotec — 360° view

Onyx Biotec, a company in the Pharmaceuticals industry, reported revenue of ₹43 crore and net profit of ₹0.94 crore for the September 2026 quarter.

Onyx Biotec (NSE: ONYX-SM) closed at ₹39.45 on 20 Nov 2026, up 2.5% over the past year. Its market capitalisation is ₹72 crore.

Share price
₹39.45 (20 Nov 2026)
Market cap
₹72 Cr (20 Nov 2026)
Revenue
₹43 Cr (September 2026 quarter)
Net profit
₹1 Cr (September 2026 quarter)
ROCE
1.15% (FY26)
ROE
-0.38% (FY26)
Book value
₹31.1 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹45.00 / ₹24.20 (20 Nov 2026)
1-year return
2.5% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: ONYX-SM

Incorporated in 2005, Onyx Biotech Ltd manufactures and sells Sterile Water for Injections, Dry Powder Injections and Dry Syrup for India and overseas, through a B2B business model

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.